34724019|t|Screening for cerebral amyloid angiopathy based on serological biomarkers analysis using a dielectrophoretic force-driven biosensor platform.
34724019|a|We aimed to analyze plasma amyloid-beta (Abeta)1-40 and Abeta1-42 using a highly sensitive dielectrophoretic-driven biosensor platform to demonstrate the possibility of precise cerebral amyloid angiopathy (CAA) diagnosis in participants classified according to Abeta-positron emission tomography (PET) positivity and the neuroimaging criteria for CAA. We prospectively recruited 25 people with non-Alzheimer's disease (non-AD) and 19 patients with Alzheimer's disease (AD), which were further classified into the CAA- and CAA+ (possible and probable CAA) groups according to the modified Boston criteria. Patients underwent plasma Abeta analysis using a highly sensitive nano-biosensor platform, Abeta-PET scanning, and detailed neuropsychological testing. As a result, the average signal levels of Abeta1-42/1-40 differed significantly between the non-AD and AD groups, and the CAA+ group exhibited significantly higher Abeta1-40 signal levels than the CAA- group in both non-AD and AD groups. The concordance between the Abeta1-40 signal level and the neuroimaging criteria for CAA was nearly perfect, with areas under the curve of 0.954 (95% confidence interval (CI) 0.856-1.000), 0.969 (0.894-1.000), 0.867 (0.648-1.000), and 1.000 (1.000-1.000) in the non-AD/CAA- vs. non-AD/possible CAA, non-AD/CAA- vs. non-AD/probable CAA, AD/CAA- vs. AD/possible CAA, and AD/CAA- vs. AD/probable CAA groups, respectively. Higher Abeta1-40 signal levels were significantly associated with the presence of CAA according to regression analyses, and the neuroimaging pattern analysis partly supported this result. Our findings suggest that measuring plasma Abeta1-40 signal levels using a highly sensitive biosensor platform could be a useful non-invasive CAA diagnostic method.
34724019	14	41	cerebral amyloid angiopathy	Disease	MESH:D016657
34724019	319	346	cerebral amyloid angiopathy	Disease	MESH:D016657
34724019	348	351	CAA	Disease	MESH:D016657
34724019	489	492	CAA	Disease	MESH:D016657
34724019	540	559	Alzheimer's disease	Disease	MESH:D000544
34724019	565	567	AD	Disease	MESH:D000544
34724019	576	584	patients	Species	9606
34724019	590	609	Alzheimer's disease	Disease	MESH:D000544
34724019	611	613	AD	Disease	MESH:D000544
34724019	655	658	CAA	Disease	MESH:D016657
34724019	664	667	CAA	Disease	MESH:D016657
34724019	692	695	CAA	Disease	MESH:D016657
34724019	747	755	Patients	Species	9606
34724019	995	997	AD	Disease	MESH:D000544
34724019	1002	1004	AD	Disease	MESH:D000544
34724019	1021	1024	CAA	Disease	MESH:D016657
34724019	1096	1099	CAA	Disease	MESH:D016657
34724019	1119	1121	AD	Disease	MESH:D000544
34724019	1126	1128	AD	Disease	MESH:D000544
34724019	1222	1225	CAA	Disease	MESH:D016657
34724019	1403	1405	AD	Disease	MESH:D000544
34724019	1406	1409	CAA	Disease	MESH:D016657
34724019	1419	1421	AD	Disease	MESH:D000544
34724019	1431	1434	CAA	Disease	MESH:D016657
34724019	1440	1442	AD	Disease	MESH:D000544
34724019	1443	1446	CAA	Disease	MESH:D016657
34724019	1456	1458	AD	Disease	MESH:D000544
34724019	1468	1471	CAA	Disease	MESH:D016657
34724019	1473	1475	AD	Disease	MESH:D000544
34724019	1476	1479	CAA	Disease	MESH:D016657
34724019	1485	1487	AD	Disease	MESH:D000544
34724019	1497	1500	CAA	Disease	MESH:D016657
34724019	1506	1508	AD	Disease	MESH:D000544
34724019	1509	1512	CAA	Disease	MESH:D016657
34724019	1518	1520	AD	Disease	MESH:D000544
34724019	1530	1533	CAA	Disease	MESH:D016657
34724019	1638	1641	CAA	Disease	MESH:D016657
34724019	1886	1889	CAA	Disease	MESH:D016657

